For many years, patients with Major Depressive Disorder faced a limited set of treatment options. Antidepressants work well for a significant proportion of patients but leave a substantial minority without adequate relief — and come with side effects that some patients find difficult to tolerate long-term. Psychotherapy is valuable but time-intensive and not always sufficient for moderate to severe depression. For people who had tried multiple medications and therapy without success, the options were historically thin. Deep TMS therapy has fundamentally changed this picture, providing a non-invasive, drug-free biological treatment that works through an entirely different mechanism than medication — and that has helped thousands of patients worldwide who had previously found no adequate path to relief.
Why Deep TMS Was First Approved for Depression
Depression holds a specific place in the history of TMS therapy: it was the first indication for which TMS received FDA clearance (in 2008), based on accumulating evidence from clinical trials showing meaningful response rates compared to sham treatment. Over subsequent years, the technology evolved from first-generation surface TMS to Deep TMS using the BrainsWay H1 coil, which reached deeper and wider brain regions for more comprehensive therapeutic effect.
The FDA clearance for Deep TMS specifically as a treatment for Major Depressive Disorder was granted in 2013, followed by additional clearances for treatment-resistant depression and for use as an adjunct to antidepressant medication. This regulatory history reflects the quality and consistency of the clinical evidence base — not a single promising trial, but repeated demonstration of clinical benefit across multiple independent studies.
The Depression Brain: What Deep TMS Targets
In major depression, neuroimaging studies consistently show reduced activity in the left dorsolateral prefrontal cortex (DLPFC) — the brain region most directly involved in mood regulation, cognitive control, and the capacity to experience positive emotion. Alongside this, the limbic system, particularly the amygdala, tends to be hyperactive — amplifying negative emotional processing and reducing positive reward response.
Deep TMS targets the left DLPFC using high-frequency stimulation designed to increase neural activity in this underactive region. By stimulating the left DLPFC repeatedly across a full treatment course, Deep TMS gradually restores more normal activity in this crucial mood-regulation circuit, with downstream effects that reduce amygdala hyperactivity and restore more balanced emotional processing.
What the Clinical Evidence Shows
The pivotal clinical trial supporting BrainsWay Deep TMS's FDA clearance for MDD demonstrated a response rate of approximately 38 percent for Deep TMS compared to 21 percent for sham treatment — a clinically and statistically significant difference. But perhaps more striking than the overall response rate is what these patients represent: most were treatment-resistant, meaning they had already tried at least one antidepressant medication without adequate relief.
Achieving meaningful response rates in a treatment-resistant population is substantially more difficult than in first-episode patients, making the clinical trial results particularly significant. Real-world clinical practice data, collected from thousands of patients treated in routine clinical settings, has shown similar or better outcomes to the trial data.
The Deep TMS Session Experience for Depression
For depression patients, a Deep TMS session typically lasts 18-20 minutes and is delivered five days per week over a course of 4-6 weeks, totaling approximately 20 sessions for the standard acute course. Unlike the OCD protocol, no provocative stimulus is used before depression sessions — the patient simply sits comfortably while the H1 coil delivers magnetic pulses to the left DLPFC.
The experience is typically described as mild scalp pressure or tapping, which most patients adapt to quickly across the first few sessions. Patients remain fully awake and alert, and can typically continue normal daily activities including driving and working immediately after each session. At Positive Mind Care, Gurugram, sessions are scheduled flexibly to accommodate professional commitments, and support is available throughout the course.
Depression Response Patterns: What to Expect
Response to Deep TMS for depression tends to follow a characteristic arc across the treatment course. The first week or two typically produce little noticeable change as the brain begins adapting to the stimulation. Around weeks two to three, many patients begin noticing subtle shifts — somewhat better sleep, slightly improved energy, a small increase in motivation or interest. From weeks three to five, these shifts typically deepen into more pronounced improvements in mood, cognition, and daily functioning.
Understanding this timeline is important for managing expectations. Patients who expect immediate dramatic change may feel discouraged during the early sessions, while those who understand the gradual neuroplastic mechanism tend to stay more consistently engaged throughout the course — which is directly associated with better outcomes.
Deep TMS as an Antidepressant Adjunct
An important and often under-discussed use of Deep TMS for depression is as an add-on to existing antidepressant medication. For patients who have a partial response to medication — some improvement but not enough — adding Deep TMS to the existing medication rather than switching medications can produce significantly better outcomes than either change alone. This combination approach is recognized in international depression treatment guidelines and is routinely offered at Positive Mind Care in Gurugram.
Deep TMS and Antidepressant Optimization
An important but often underappreciated use case for Deep TMS is in patients who have a partial response to antidepressants — some improvement but not full remission. Rather than switching medications or adding a second medication (augmentation), adding Deep TMS to an existing antidepressant regimen can convert a partial response into full remission for a significant proportion of patients.
This adjunctive use of Deep TMS reflects its different mechanism — while the antidepressant is working through the neurotransmitter pathway it has already partially optimized, Deep TMS adds direct neural circuit stimulation, reaching the biological dimension of depression through a complementary route. The combination can achieve what neither alone managed, while avoiding the additional side effect burden of medication augmentation.
Frequently Asked Questions
Q1. How does Deep TMS compare to ECT for depression? ECT (electroconvulsive therapy) remains more effective for the most severe, acutely life-threatening depression cases. Deep TMS is a preferable option for the broad middle range of moderate to severe depression, and particularly for treatment-resistant cases where the patient is not in immediate crisis — offering meaningful efficacy with a dramatically better side effect profile.
Q2. Will I need to stop my current medication for Deep TMS? Generally no. Deep TMS is safe to combine with most antidepressant medications, and the combination often produces better results than either alone.
Q3. How many sessions does a full depression Deep TMS course involve? A standard acute course involves approximately 20 sessions over 4-6 weeks. Some patients benefit from an extended course or maintenance sessions, depending on their clinical response.
Q4. Is Deep TMS for depression covered by insurance in India? Coverage varies by policy and insurer. It is worth checking with your specific provider, as awareness and coverage for TMS therapy are increasing.
Conclusion
Deep TMS therapy for depression is no longer experimental — it is an established, FDA-cleared, evidence-based treatment that has helped thousands of patients worldwide who didn't find adequate relief from medication. In Gurugram, Positive Mind Care brings this technology directly to patients who need it, with experienced psychiatrists providing individualized treatment programs that have made a meaningful difference for many patients who had run out of other options.